Medical Condition News

RSS

Microglia plays a key role in memory and learning

Immune system cells of the brain, which scavenge pathogens and damaged neurons, are also key players in memory and learning, according to new research by Duke neuroscientists.

27 Oct 2011

Innovative trial project of MD-Logic Artificial Pancreas takes place in Israel

At the initiative, and under the leadership of specialists in the Jesse Z and Sara Lea Shaffer Institute for Endocrinology and Diabetes, National Center of Childhood Diabetes, Schneider Children's Medical Center, an innovative trial project of the MD-Logic Artificial Pancreas (MDLAP) has successfully taken place in Israel.

27 Oct 2011

Annual chest radiographic screening does not reduce lung cancer mortality

In a trial that included more than 150,000 participants, those who underwent annual chest radiographic screening for up to 4 years did not have a significantly lower rate of death from lung cancer compared to participants who were not screened, according to a study in the November 2 issue of JAMA.

27 Oct 2011

Researchers uncover molecular pathway critical to cardiac arrhythmia

University of Maryland School of Medicine researchers have uncovered a previously unknown molecular pathway that is critical to understanding cardiac arrhythmia and other heart muscle problems.

27 Oct 2011

Penn Nursing experts available to discuss stories on American Diabetes Month

Diabetes specialists at the University of Pennsylvania School of Nursing are available to talk with media for stories on American Diabetes Month.

27 Oct 2011

U of A researchers discover potential new drug target for MS

Medical researchers at the University of Alberta have discovered a potential new drug target for Multiple Sclerosis that could prevent physical disability associated with the disease, once a new drug is developed.

27 Oct 2011

Medtronic initiates Symplicity System clinical study in treatment-resistant hypertension

Medtronic Inc. announced today the start of SYMPLICITY HTN-3, the company's U.S. clinical trial of the Symplicity Renal Denervation System for treatment-resistant hypertension.

From Medtronic 27 Oct 2011

Nanoparticles could help increase retention of osteoarthritis drugs in knee cavity

A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive.

27 Oct 2011

E. coli asparaginase linked to relapses in ALL patients with special form of ATF5 gene

One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when treated with E. coli asparaginase, a key chemotherapy drug for this type of leukemia.

27 Oct 2011

Scripps researcher receives U-M's Eric J. Topol Professorship in Cardiovascular Medicine

The University of Michigan Medical School today announced the establishment of the Eric J. Topol Professorship in Cardiovascular Medicine. A world-renowned cardiologist, Dr. Topol is currently chief academic officer at Scripps Health and a senior cardiologist practitioner at Scripps Clinic.

27 Oct 2011

Cancer experts say needs of younger patients slighted

Physicians and researchers acknowledge that for decades, the needs of adolescents and young adults with cancer have been slighted. They frequently receive inconsistent treatment and follow-up care, and clinical trials and research focused on this age group have been scarce, according to oncologists and a report by the National Cancer Institute.

27 Oct 2011

Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint

Onyx Pharmaceuticals, Inc. today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.

27 Oct 2011

International diabetes researchers to engineer artificial pancreas system

The National Institutes for Health (NIH) have awarded $4.5 million to a group of international diabetes researchers to engineer an artificial pancreas system that will monitor and adapt to the body's complex real-time changes in behavior and physiology.

27 Oct 2011

New potential leukemia therapy targets and kills cancer cells

A new potential leukemia therapy targets only cancer cells, while leaving healthy cells alone. Many current chemotherapy treatments affect cancer cells and healthy cells, causing significant side effects, such as fatigue, hair loss, nausea, anxiety and depression.

27 Oct 2011

Clinical and genetic risk factors associated with early stent thrombosis

Patients with certain genes or specific factors related to use of the anti-clotting drug clopidogrel are more likely to experience a blood clot within a coronary stent shortly after placement, according to a study in the October 26 issue of JAMA.

27 Oct 2011

Blood biomarker panel can predict survival in IPF patients

A panel of blood proteins can predict which patients with the progressive lung disease idiopathic pulmonary fibrosis (IPF) are likely to live at least five years or to die within two years, say researchers at the University of Pittsburgh School of Medicine and Centocor R&D.

27 Oct 2011

Largest study on diabetes and foot ulcers

What's crucial for a diabetic's foot sore to heal is that the ulcer is superficial, blood circulation is normal, and the person has had diabetes for short time. This is shown in the world's largest diabetes study regarding foot ulcers, which has been carried out by the researcher Magdalena Annersten Gerhater at Malmö University in Sweden.

27 Oct 2011

Henry Ford becomes first U.S. hospital to offer skin transplant surgery for vitiligo

Henry Ford Hospital is the first in the country to offer skin transplant surgery as part of its treatment portfolio for patients with the skin disease vitiligo.

27 Oct 2011

FDA responds to Delcath's request for pre-NDA meeting

Delcath Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has responded to the Company's request made in September for a pre-New Drug Application (NDA) meeting and has scheduled a date in mid-January 2012.

27 Oct 2011

Insulin resistance paradox

Obesity and insulin resistance are almost inevitably associated with increases in lipid accumulation in the liver, a serious disease that can deteriorate to hepatitis and liver failure. A real paradox in understanding insulin resistance is figuring out why insulin-resistant livers make more fat. Insulin resistance occurs when the body does a poor job of lowering blood sugars.

27 Oct 2011